Homozygous neoR transgenic mice (TgN3Ems) are viable and fertile with no apparent gross phenotype. The pPGKneobpA transgene has the mouse Pgk1 promoter directing widespread (but not necessarily uniform) expression of neoR: this renders TgN3Ems mice highly G418-resistant and results in a 5-fold increase in the approximate lethal dose of G418 (~480 mg/kg) compared to wildtype mice (~103 mg/kg). Treatment with G418 lethal dose (or higher) in transgenic mice leads to rapid onset of decreased movement, respiratory arrest, and death within minutes. Compared to wildtype mouse embryonic fibroblasts (MEFs), TgN3Ems MEFs exhibit greatly diminished G418 sensitivity: wildtype MEFs show essentially no resistance to G418 while TgN3Ems MEFs survive approximately 20-fold higher G418 levels. Importantly, TgN3Ems heterozygotes and TgN3Ems homozygotes are equally resistant to G418. These TgN3Ems transgenic mice may be useful as source of G418-resistant feeder cells for gene targeting; specifically TgN3Ems MEFs may be ideal for two-allele, as well as for standard, targeting due to their high resistance to selection drugs. Additionally, because the expression of drug-resistance genes in transgenic animals confers resistance to toxicity, the TgN3Ems mice may also serve as a tool strain for testing drug design.

These TgN3Ems transgenic mice express a neomycin resistance cassette (neoR), rendering the mice resistant to the lethal effects of the neomycin analog, G418. These TgN3Ems mice may be useful in drug design.

Typically mice are recovered in 12-16 weeks. Contact Customer Service to place an order or for more information.

<a target="_blank" href="https://www.jax.org/jax-mice-and-services/customer-support" rel="noreferrer">Contact Customer Service</a> for more information.